



FIRM REPORT: THE LINE BETWEEN BIO AND TECHNOLOGY

Publications

15, October 2024

The question of what the biotechnology industry can patent ripened into a broad industry debate after two landmark Supreme Court decisions – *Mayo Collaborative Servs v. Prometheus Labs., Inc.* (2012) and *Alice Corp. v. CLS Bank International* (2014). Their collective holding – that under 35 U.S.C. § 101, inherently natural phenomena cannot be patented, even with the addition of previously known secondary technologies – led to the invalidation of numerous patents and likely narrowed the scope of what can be patented in the future. [View the PDF article](#) in its entirety.

RELATED SERVICES

Intellectual Property

Technology